Lupus & antiphospholipid syndrome
Prognostic Value of Lupus Anticoagulant and Anti–β2 Glycoprotein I Antibody in Adverse Pregnancy Outcomes
Authors' conclusion
LA-RVVT, anti-β2GPI IgG, complications including hypertension, and a history of IUFD were valuable in identifying obstetric APS.
Study context
- Population
- Pregnant women not using heparin (those with an obstetric antiphospholipid syndrome (APS) diagnosis before pregnancy excluded), enrolled July 2021–March 2024
- Participants
- 1,237 participants
- Outcome
- Prognostic value of commercially available aPL-related tests for obstetric APS (early-onset preeclampsia, IUFD, small for gestational age)
Methodological detailsPregnancy outcomes followed until December 2024
- Pregnancy outcomes followed until December 2024
Main finding
As reported in the abstract
Adverse pregnancy outcomes: prevalence and aPL predictors
Early-onset preeclampsia prevalence
1.4%
17
Intrauterine fetal death (IUFD) prevalence
0.7%
9
Small for gestational age prevalence
0.9%
11
AUC when combined with a history of preeclampsia or IUFD, respectively
about 0.8
Observational data: associations, not effects.
Original publication
Prognostic Value of Lupus Anticoagulant and Anti–β2 Glycoprotein I Antibody in Adverse Pregnancy Outcomes. Arthritis Rheumatol. Published 21 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →